ALSPW Spineway SAS

Spineway : Minutes of the General Meeting of June 4, 2025

Spineway : Minutes of the General Meeting of June 4, 2025

Press release        

Ecully, June 6, 2025 – 6.00 p.m.

 

SPINEWAY

Minutes of the General Meeting of June 4, 2025

The Combined General Meeting (Ordinary and Extraordinary) of Spineway shareholders was held on first notice on Wednesday, June 4, 2025 at 2:00 p.m at the company’s registered office, 7 allée Moulin Berger in Ecully (69).

The defaulting shareholders were represented by SELARL TULIER POLGE ALIREZAI, as ad hoc representative appointed by Order of the President of the Lyon Commercial Court dated April 30, 2025. The number of shares held by shareholders present, represented and voting by mail was 34,383,058, representing 100% of voting rights. The quorum having been reached, the Meeting was able to proceed and deliberate normally.

Resolutions 1, 2, 3, 4, 6, 7, 8, 14, 15, 20 and 21 were approved by shareholders. Resolutions 5, 9, 10, 11, 12, 13, 16, 17, 18 and 19 were rejected.

Information relating to the Combined General Meeting is available on the Company’s website under “Investors/Regulated Information”: .

Next dates:

July 30, 2025 - Half-year sales 2025

SPINEWAY IS ELIGIBLE FOR PEA-SME (EQUITY SAVINGS PLANS FOR SMES)

Find out all about Spineway at

This press release has been prepared in both English and French. In case of discrepancies, the French version shall prevail.

Spineway designs, manufactures and markets innovative implants and surgical instruments for treating severe disorders of the spinal column.

Spineway has an international network of over 50 independent distributors and 70% of its revenue comes from exports.

ISIN: FR001400N2P2 - ALSPW        

Contacts:



SPINEWAY



Shareholder-services line

Available Tuesday through Thursday

+33 (0)806 706 060
 

AELIUM



Investor relations

Solène Kennis

Attachment



EN
06/06/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Spineway SAS

 PRESS RELEASE

SPINEWAY : Chiffre d’affaires annuel 2025 de 12,4 ME avec une accéléra...

SPINEWAY : Chiffre d’affaires annuel 2025 de 12,4 ME avec une accélération des ventes au T4 2025 (+34%) Ecully, le 13 janvier 2026 – 18h30 SPINEWAY Chiffre d’affaires annuel 2025 de 12,4 M€ avec une accélération des ventes au T4 2025 (+34%) En milliers d’euros20252024Variation en %CA 1er semestre5 5736 535- 15%CA 2ème semestre6 8575 415+ 27%CA annuel12 43011 950+ 4% Données consolidées non auditées Au dernier trimestre 2025, Spineway, spécialiste des implants innovants pour le traitement des pathologies de la colonne vertébrale (rachis), a bénéficié d’une accélération des ventes sur l...

 PRESS RELEASE

SPINEWAY : 2025 revenue of €12.4 million,  with an acceleration of sal...

SPINEWAY : 2025 revenue of €12.4 million,  with an acceleration of sales in Q4 2025 (+34%) Ecully, January 13, 2026 – 6:30 p.m. SPINEWAY 2025 revenue of €12.4 million, with an acceleration of sales in Q4 2025 (+34%) In thousands of euros20252024Change as a %H1 revenue5,5736,535-15%H2 revenue6,8575,415+27%Full-year revenue12,43011,950+4% Unaudited consolidated data In the final quarter of 2025, Spineway, a specialist in innovative implants for the treatment of severe spine disorders, benefited from an acceleration in sales across all of its markets and the receipt of key account orders d...

 PRESS RELEASE

SPINEWAY : Evolution Surgical distribuera les prothèses discales CP-ES...

SPINEWAY : Evolution Surgical distribuera les prothèses discales CP-ESP et LP-ESP en Australie  Ecully, le 22 octobre 2025 – 8h30 SPINEWAY Evolution Surgical distribuera les prothèses discales CP-ESP et LP-ESP de Spineway en Australie  Spineway, spécialiste des implants innovants pour le traitement des pathologies sévères de la colonne vertébrale (rachis), annonce la conclusion d'un accord avec Evolution Surgical, pour la distribution exclusive de ses prothèses discales ESP en Australie à partir du 25 octobre 2025. Orthotech, l’ancien distributeur sur cette zone, assurera en collaboratio...

 PRESS RELEASE

Spineway : Revenue growth in the third quarter

Spineway : Revenue growth in the third quarter Ecully, October 14, 2025 – 6:30 p.m. SPINEWAYRevenue growth in the third quarter In thousands of euros20252024Change as a %Q3 revenue3,0452,575   +18%Q2 revenue2,7453,465-21% Q1 revenue2,8283,070-8%9M revenue8,6189,110      -5% Unaudited consolidated data The Spineway Group, a specialist in innovative implants for the treatment of severe spine disorders, benefited, in line with its expectations, from a deferral of orders from major accounts to the third quarter of 2025 and generated revenue of €3.0 million over the period, up from €2.6 millio...

 PRESS RELEASE

SPINEWAY : Croissance du chiffre d’affaires au 3ème trimestre

SPINEWAY : Croissance du chiffre d’affaires au 3ème trimestre Ecully, le 14 octobre 2025 – 18h30 SPINEWAYCroissance du chiffre d’affaires au 3ème trimestre En milliers d’euros20252024Variationen %CA 3ème trimestre3 0452 575   + 18%CA 2ème trimestre2 7453 465- 21%CA 1er trimestre2 8283 070      - 8%CA 9 mois8 6189 110       - 5% Données consolidées non auditées Spineway, spécialiste des implants innovants pour le traitement des pathologies sévères de la colonne vertébrale (rachis), a bénéficié, conformément à ses anticipations, d’un report des commandes de grands comptes sur le 3ème trimes...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch